Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

Conditions:   Primary Immune Deficiency Disorders;   Hemophagocytic Lymphohistiocytosis;   Inherited Bone Marrow Failure Syndrome;   Hemoglobinopathies;   Metabolic DisordersIntervention:   Biological: BPX-501 and AP1903Sponsor:   Bellicum PharmaceuticalsNot yet recruiting - verified September 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials